LIN28A and neoplasm: As LIN28AB expression is limited predominantly to tumor cells and conditional mouse knockout of either Lin28a or Lin28b at 6 weeks of age yields no overt phenotypes, it is anticipated that therapeutics targeting the LIN28/let-7 pathway will have minimal side effects in patients.